JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3009 Sorafenib
2 Citation

Target: Raf|VEGFR

Summary: Raf kinases and tyrosine kinases inhibitor

≥23.25 mg/mL
A3022 Pazopanib (GW-786034)

Target: CSF-1R|VEGFR|PDGFR|c-Kit|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in EtOH; insoluble in H2O; ≥10.95 mg/mL
A4147 LY2784544

Target: Aurora Kinases|FLT3|VEGFR|FGFR|Trk Receptors|JAK|ALK|TYK2|MUSK|MAP3K

Summary: JAK2 inhibitor,highly potent and selective

≥23.5 mg/mL
A4150 WHI-P154

Target: VEGFR|Src|EGFR|JAK

Summary: JAK3 inhibitor

insoluble in H2O; insoluble in EtOH; ≥125.6 mg/mL
A4125 CYC116

Target: Aurora Kinases|FLT3|VEGFR

Summary: Potent Aurora A/B inhibitor

insoluble in EtOH; insoluble in H2O; ≥18.4 mg/mL
B4904 ACTB-1003

Target: VEGFR|FGFR|Tie-2|RSK|p70 S6K

Summary: FGFR1 inhibitor

insoluble in H2O; ≥18.15 mg/mL
B5832 Altiratinib
1 Citation

Target: FLT3|VEGFR|Trk Receptors|c-MET|Tie-2

Summary: c-MET/TIE-2/VEGFR inhibitor

≥21.55 mg/mL
B5835 AZD2932

Target: FLT3|VEGFR|PDGFR|c-Kit

Summary: inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit

Soluble in DMSO
B5864 Fruquintinib(HMPL-013)

Target: VEGFR

Summary: Potent and selective inhibitor of VEGFR 1, 2, 3

insoluble in H2O; insoluble in EtOH; ≥6.35 mg/mL
B5953 Dovitinib (TKI258) Lactate

Target: CSF-1R|FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Oral tyrosine kinase inhibitor (TKI) against FGFR1–3, VEGFR1–3, and platelet-derived growth factor receptor (PDGFR).

insoluble in EtOH; ≥10.62 mg/mL